Non-Hodgkin's Lymphoma (NHL) Pipeline Insight

DelveInsight’s, “Non-Hodgkin Lymphoma- Pipeline Insight, 2025” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Non-Hodgkin Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

 

Non-Hodgkin Lymphoma: Understanding

Non-Hodgkin Lymphoma: Overview

Non-Hodgkin Lymphoma (NHL) encompasses a heterogeneous group of lymphoid malignancies that originate from B lymphocytes, T lymphocytes, or natural killer cells. It is classified into more than 60 distinct subtypes based on cell origin, growth rate, and molecular features. NHL is broadly divided into two categories: indolent (slow-growing) lymphomas, such as follicular lymphoma and marginal zone lymphoma, and aggressive (fast-growing) lymphomas, such as diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma. B-cell lymphomas account for the majority of NHL cases, while T-cell and natural killer cell lymphomas are less common.

The presentation of NHL varies based on the subtype and disease stage. Common symptoms include painless lymphadenopathy (swollen lymph nodes) in areas like the neck, armpit, or groin. Systemic ""B symptoms,"" such as unexplained fever, drenching night sweats, and significant weight loss (>10% of body weight in six months), are often observed in aggressive forms. Other symptoms may include fatigue, abdominal pain or swelling due to lymph node enlargement, and chest pain or shortness of breath if mediastinal nodes are involved. Indolent types may remain asymptomatic for prolonged periods.

The exact cause of NHL is not known, but there are risk factors that may increase the likelihood of developing the disease. Factors affecting people’s risk of developing NHL have been studied extensively. Some of these factors are immune disorders, medicines, infections, lifestyle, genetics, race, family history and occupational factors. Some risk factors differ by subtype.

NHL arises from the malignant transformation of lymphocytes at various stages of differentiation, leading to clonal expansion. Genetic mutations, chromosomal translocations (e.g., t(14;18) in follicular lymphoma), and dysregulation of oncogenes such as BCL-2 or MYC play a central role in disease pathogenesis. These changes lead to uncontrolled cell proliferation, evasion of apoptosis, and immune evasion. The microenvironment within lymphoid tissues further supports tumor growth and survival through cytokine signaling and immune suppression.

The diagnosis of NHL involves a combination of clinical evaluation, imaging, and pathological analysis. Excisional biopsy of an affected lymph node or tissue is the gold standard, with immunohistochemistry and flow cytometry used to determine the subtype. Staging is performed using imaging techniques like computed tomography (CT) or positron emission tomography (PET) scans, and bone marrow biopsy is often done to assess marrow involvement. The Ann Arbor staging system is commonly used to classify the extent of disease.

The treatment of NHL depends on the subtype, stage, and patient-specific factors like age and comorbidities. Indolent types may be managed with ""watchful waiting"" until symptoms develop, while aggressive types require immediate intervention. Common treatments include chemotherapy regimens like R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), targeted therapies such as monoclonal antibodies, and radiation therapy. In refractory or relapsed cases, newer treatments like CAR-T cell therapy or stem cell transplantation may be employed. Treatment advancements have significantly improved survival rates, especially in aggressive subtypes.

 

"Non-Hodgkin Lymphoma- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Non-Hodgkin Lymphoma pipeline landscape is provided which includes the disease overview and Non-Hodgkin Lymphoma treatment guidelines. The assessment part of the report embraces, in depth Non-Hodgkin Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Non-Hodgkin Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Non-Hodgkin Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Non-Hodgkin Lymphoma.

 

Non-Hodgkin Lymphoma Emerging Drugs Chapters

This segment of the Non-Hodgkin Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Non-Hodgkin Lymphoma Emerging Drugs

• Golcadomide: Bristol Myers Squibb

Golcadomide is a novel cereblon E3 ligase modulator (CELMoD) being investigated for the treatment of aggressive B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL). In combination with R-CHOP chemotherapy, it has shown promising antitumor activity in high-risk DLBCL patients, with a high overall response rate (ORR) and complete metabolic response (CMR). Currently, the drug is in Phase III stage of its clinical trial for the treatment of Non-Hodgkin Lymphoma.

 

• MEN 1703: Ryvu Therapeutics

MEN1703 (SEL24) is a clinical-stage program discovered and developed by Ryvu Therapeutics and licensed to the Menarini Group. MEN1703 is a first-in-class, dual PIM/FLT3 kinase inhibitor with a unique activity profile. By design, this profile may provide responses to treatment that are more durable than current options and address a disease that has progressed following FLT3 inhibition. Preclinical data suggests therapeutic potential in both hematological malignancies and in solid tumors. Ryvu has granted the Menarini Group an exclusive worldwide license to further research, develop, manufacture and commercialize MEN1703 (SEL24). Currently the drug is in Phase II stage of its clinical development for the treatment of B-cell Non-Hodgkin Lymphoma.

 

• LP-168: Guangzhou Lupeng Pharmaceutical

LP-168 is a third-generation, orally active, irreversible EGFR tyrosine kinase inhibitor (TKI) developed by Guangzhou Lupeng Pharmaceutical for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations, including T790M resistance mutations. It is designed to target mutant EGFR while sparing wild-type EGFR, potentially reducing side effects. LP-168 has shown promising preclinical activity and is currently in clinical trials. The company is exploring its use in both first-line and resistant EGFR-mutant NSCLC settings. Currently the drug is in Phase II stage of its clinical development for the treatment of B-cell Non-Hodgkin Lymphoma.

 

• DR-0201: Dren Bio

DR-0201 is an investigational drug developed by D.R. Pharmatech, designed as a novel anti-cancer agent targeting HER2-expressing tumors, particularly in gastric and breast cancers. It is a HER2-targeting antibody-drug conjugate (ADC) that combines a monoclonal antibody with a cytotoxic payload to selectively kill cancer cells while minimizing damage to healthy tissue. DR-0201 aims to overcome resistance seen with existing HER2 therapies. The product is currently undergoing preclinical or early-phase clinical evaluation. Currently the drug is in Phase I stage of its clinical development for the treatment of B-cell Non-Hodgkin Lymphoma.

 

• ETR-7072: EntreChem

ETR-7072 is an investigational small-molecule drug developed by EntreChem, designed to target cancer by modulating transcriptional programs involved in tumor growth and survival. It is part of EntreChem’s novel class of natural product-inspired compounds with multi-targeted activity, potentially affecting epigenetic regulators and oncogenic pathways. ETR-7072 shows promise in preclinical models for treating aggressive and resistant cancers. The compound is currently in early-stage development, with ongoing studies to assess its safety and efficacy. Currently the drug is in Preclinical stage of its clinical development for the treatment of B-cell Non-Hodgkin Lymphoma.

Further product details are provided in the report……..

 

Non-Hodgkin Lymphoma: Therapeutic Assessment

This segment of the report provides insights about the different Non-Hodgkin Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:

Major  Players in Non-Hodgkin Lymphoma

There are approx. 180+ key companies which are developing the therapies for Non-Hodgkin Lymphoma. The companies which have their Non-Hodgkin Lymphoma drug candidates in the most advanced stage, i.e. Phase III include, Bristol Myers Squibb.

 

Phases

DelveInsight’s report covers around 200+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Non-Hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

 

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Non-Hodgkin Lymphoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Non-Hodgkin Lymphoma therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Non-Hodgkin Lymphoma drugs.

 

Non-Hodgkin Lymphoma Report Insights

• Non-Hodgkin Lymphoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

 

Non-Hodgkin Lymphoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Non-Hodgkin Lymphoma drugs?
• How many Non-Hodgkin Lymphoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Non-Hodgkin Lymphoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Non-Hodgkin Lymphoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Non-Hodgkin Lymphoma and their status?
• What are the key designations that have been granted to the emerging drugs?